Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5H9TE
|
|||
| Drug Name |
BI 1291583
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Non-cystic fibrosis bronchiectasis [ICD-11: CA24; ICD-10: J47; ICD-9: 494] | Phase 2 | [1] | |
| Company |
boehringer-ingelheim
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dipeptidyl peptidase I (CTSC) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Lysosome | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
| MHC class II antigen presentation | ||||
| Cargo concentration in the ER | ||||
| WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05238675) A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study Evaluating Efficacy, Safety and Tolerability of BI 1291583 qd Over at Least 24 Weeks in Patients With Bronchiectasis (AirleafTM). U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of boehringer-ingelheim | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.